Melatonin Reverses the Profibrillogenic Activity of Apolipoprotein E4 on the Alzheimer Amyloid Aβ Peptide
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Inheritance of apoE4 is a strong risk factor for the development of late-onset sporadic Alzheimer's disease (AD). Several lines of evidence suggest that apoE4 binds to the Alzheimer Abeta protein and, under certain experimental conditions, promotes formation of beta-sheet structures and amyloid fibrils. Deposition of amyloid fibrils is a critical step in the development of AD. We report here that addition of melatonin to Abeta in the presence of apoE resulted in a potent isoform-specific inhibition of fibril formation, the extent of which was far greater than that of the inhibition produced by melatonin alone. This effect was structure-dependent and unrelated to the antioxidant properties of melatonin, since it could be reproduced neither with the structurally related indole N-acetyl-5-hydroxytryptamine nor with the antioxidants ascorbate, alpha-tocophenol, and PBN. The enhanced inhibitory effects of melatonin and apoE were lost when bovine serum albumin was substituted for apoE. In addition, Abeta in combination with apoE was highly neurotoxic (apoE4 > apoE3) to neuronal cells in culture, and this activity was also prevented by melatonin. These findings suggest that reductions in brain melatonin, which occur during aging, may contribute to a proamyloidogenic microenvironment in the aging brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268
Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107
Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease
Gomez‐Isla, T., West, H. L., Rebeck, G. W., Harr, S. D., Growdon, J. H., Locascio, J. J., Perls, T. T., Lipsitz, L. A., & Hyman, B. T. (1996) · Annals of Neurology · doi:10.1002/ana.410390110 · Cited by 378
Amyloid β binding proteins in vitro and in normal human cerebrospinal fluid
Golabek, A., Marques, M. A., Lalowski, M., & Wisniewski, T. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11565-7 · Cited by 99
Cited by
Melatonin: Nature’s most versatile biological signal?
Pandi‐Perumal, S. R., Srinivasan, V., Maestroni, G. J. M., Cardinali, D. P., Poeggeler, B., & Hardeland, R. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05322.x · Cited by 875
Neuropathogenesis of Delirium: Review of Current Etiologic Theories and Common Pathways
Maldonado, J. R. (2013) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.09.005 · Cited by 745
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
Melatonin and inflammation-Story of a double-edged blade
Hardeland, R. (2018) · Journal of Pineal Research · doi:10.1111/jpi.12525 · Cited by 455
Suofu, Y., Li, W., Jean-Alphonse, F. G., Jia, J., Khattar, N. K., Li, J., Baranov, S. V., Leronni, D., Mihalik, A. C., He, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705768114 · Cited by 414
Nutritional approaches to combat oxidative stress in Alzheimer’s disease
Butterfield, D. A., Castegna, A., Pocernich, C. B., Drake, J., Scapagnini, G., & Calabrese, V. (2002) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(02)00205-x · Cited by 403
Matsubara, E., Bryant‐Thomas, T., Pacheco Quinto, J., Henry, T. L., Poeggeler, B., Herbert, D., Cruz‐Sanchez, F., Chyan, Y., Smith, M. A., Perry, G., et al. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01654.x · Cited by 332
Self-citationPandi-Perumal, S. R., BaHammam, A. S., Brown, G. M., Spence, D. W., Bharti, V. K., Kaur, C., Hardeland, R., & Cardinali, D. P. (2013) · Neurotoxicity Research · doi:10.1007/s12640-012-9337-4 · Cited by 320
Alzheimer’s disease: pathological mechanisms and the beneficial role of melatonin
Rosales‐Corral, S. A., Acuña‐Castroviejo, D., Coto‐Montes, A., Boga, J. A., Manchester, L. C., Fuentes‐Broto, L., Korkmaz, A., Ma, S., Tan, D. X., & Reiter, R. J. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00937.x · Cited by 294
A Review of Melatonin, Its Receptors and Drugs
Emet, M., Ozcan, H., Ozel, L., Yayla, M., Halici, Z., & Hacimuftuoglu, A. (2019) · The Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2015.0267 · Cited by 291
Olcese, J. M., Cao, C., Mori, T., Mamcarz, M. B., Maxwell, A., Runfeldt, M. J., Wang, L., Zhang, C., Lin, X., Zhang, G., et al. (2009) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2009.00692.x · Cited by 260
Antioxidants as treatment for neurodegenerative disorders
Moosmann, B., & Behl, C. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.10.1407 · Cited by 252
Role of melatonin in neurodegenerative diseases
Srinivasan, V., Pandi-Perumal, S. R., Maestroni, G. J. M., Esquifino, A. I., Hardeland, R., & Cardinali, D. P. (2005) · Neurotoxicity Research · doi:10.1007/bf03033887 · Cited by 235
“…interactions with other free radicals, secondarily scavenge the superoxide anion radical and nitrogen dioxide (Hardeland et al., 1993; Tan et al., 1993; 2000; 2002; Hardeland and Fuhrberg, 1996; Zhang et al., 1998; 1999; Blanchard et al., 2000; Poeggeler et al., 2002; Reiter et al., 2003b).”
BackgroundMelatonin in Alzheimer's disease and other neurodegenerative disorders
Srinivasan, V, Pandi-Perumal, Sr., Cardinali, D., Poeggeler, B., & Hardeland, R. (2006) · Behavioral and Brain Functions · doi:10.1186/1744-9081-2-15 · Cited by 223
Self-citationCurrent drug targets for Alzheimer's disease treatment
Lahiri, D. K., Farlow, M. R., Greig, N. H., & Sambamurti, K. (2002) · Drug Development Research · doi:10.1002/ddr.10081 · Cited by 222
“An endogenous melatonin-related indole structure, indole-3-propionic acid, has shown potent neuroprotective properties against Ab [Chyan et al., 1999] and, also, it appears that melatonin may reverse the profibrillogenic activity of apolipoprotein e4 on Ab peptide [Poeggeler et al., 2001].”
BackgroundOno, K., Hamaguchi, T., Naiki, H., & Yamada, M. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.002 · Cited by 184
“In addition, it has been shown that melatonin inhibits the formation of β-sheets and amyloid fibrils in vitro by using Fourier transform infra-red spectroscopy and EM [138,139].”
Graphene quantum dots for the inhibition of β amyloid aggregation
Liu, Y., Xu, L.-P., Dai, W., Dong, H., Wen, Y., & Zhang, X. (2015) · Nanoscale · doi:10.1039/c5nr06282a · Cited by 162
Circadian disruption and human health: A bidirectional relationship
Abbott, S. M., Malkani, R. G., & Zee, P. C. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14298 · Cited by 161
Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases
Chen, D., Zhang, T., & Lee, T. H. (2020) · Biomolecules · doi:10.3390/biom10081158 · Cited by 140
“Inhibiting apoptosis Cell Bax/bcl-2/caspase-3 Pharma [21] Inhibiting Aβ neurotoxicity Cell Pin1/GSK3β/NF-κB Physio [57] Inhibiting amyloid fibrils Cell Apoe4 Pharma [59] Inhibiting apoptosis Animal Bax/caspase-3/Par-4 Pharma [60] Inhibiting tau hyperphosphorylation Cell GSK-3β Pharma [61] Inhibiting tau hyperphosphory…”
BackgroundOxidant/antioxidant imbalance and the risk of Alzheimer's disease
Moneim, A. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150325182702 · Cited by 136
Neuroinflammation: a potential therapeutic target
Craft, J. M., Watterson, D. M., & Van Eldik, L. J. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.5.887 · Cited by 116
“Relevant to AD, melatonin decreases the ability of apolipoprotein ε4 to act as a profibrillogenic factor for Aβ [93].”
BackgroundOxidative Stress in Alzheimer’s Disease: The Shortcomings of Antioxidant Therapies
Pappolla, M. A., Martins, R. N., Poeggeler, B., Omar, R. A., & Perry, G. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-240659 · Cited by 29
Self-citation
Metadata
- Authors
- Poeggeler, B., Miravalle, L., Zagorski, M. G., Wisniewski, T., Chyan, Y.-J., Zhang, Y., Shao, H., Bryant-Thomas, T., Vidal, R., Frangione, B., Ghiso, J., & Pappolla, M. A.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2001-11-15
- Volume
- 40
- Issue
- 49
- Pages
- 14995-15001
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2116119567
- Cited by
- 153
- References
- 4
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.